A study revealed on Friday that a single dose of Pfizer/BioNTech’s COVID-19 vaccine can reduce the transmission risk of novel coronavirus effectively.
A single dose of the Pfizer coronavirus vaccine has shown a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers says the authors of the study.
The study was conducted by UK researchers that analysed the results from thousands of COVID-19 tests that were carried out on a weekly basis for the healthcare staffers at a hospital in Cambridge, eastern England.
However, the study result showed that around 0.80% of tests from those healthcare workers who were not vaccinated were found to be COVID-19 positive, while on the other hand only 0.37% of tests were found positive among those who were vaccinated among the healthcare staffers.
One of the researchers was quoted as saying, “The study has also revealed that the level of asymptomatic infection was also halved in those vaccinated for less than 12 days”.
The Pfizer vaccine is also competent for all those who have had COVID-19, said the study authors. “For all those who have had COVID-19, a single dose of the Pfizer vaccine is enough to provide robust protection from the coronavirus,” an expert expressed.
The study comes days after another study that showed Pfizer and BioNTech’s Covid-19 vaccine is 94 per cent efficient.
It has been directed by the vaccine makers that two doses of the vaccine can help in providing full immunity against the novel coronavirus.
According to the health expert, “Two doses of Pfizer/BioNTech’s COVID-19 vaccine is recommended to be taken in a gap period of 21 days. The first dose will protect an individual against Covid-19, the first dose primes the immune system and the second boost it.”
However, the US Food and Drug Administration has not approved the Pfizer-BioNTech Covid-19 vaccine but it has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Covid-19 for use in individuals 16 years of age and older.
In the UK, the Pfizer COVID-19 vaccine was rolled out in late December 2020.